how does tirzepatide differ from semaglutide vs. for Obesity Tirzepatide vs Semaglutide: What's the

Metabolic Changes Clinical studies may monitor blood sugar, insulin response, cholesterol, and other metabolic measurements

After matching 168,428 patients in each group, GLP-1 receptor agonist users had a VTE rate of 11.0 per 1,000 patient-years compared to 12.9 per 1,000 patient-years in those taking DPP-4 inhibitors (a different class of diabetes medication)

Reference: FDA Safe Cold Storage for Medications 4

GLP-1 medications were originally developed to treat type 2 diabetes, but are also widely prescribed for weight loss

GLP-1 receptors being widely available in the different organs and tissues such as the brain, lung, pancreas, stomach, heart, and endometrium has explained the broader therapeutic application of GLP-1RA